Skip to main content
Equibles

Balyasny Asset Management L.P.

Position in REPL — Replimune Group, Inc.

CIK 1218710 Chicago, IL
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$452,242
+$216,485 QoQ
Shares Held
40,853
+32.6% QoQ
Ownership
0.043%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#83
of 199 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $2,351,657,469 across 178 Biotechnology names. REPL ranks #153 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 APGE
Apogee Therapeutics, Inc.
 1,665,102 $221,008,988
2 INSM
INSMED Inc
 1,326,430 $141,423,966
3 BBIO
BridgeBio Pharma, Inc.
 1,230,052 $91,614,272
4 ABVX
Abivax S.A.
 603,840 $80,467,718
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 145,005 $72,028,333
6 TNGX
Tango Therapeutics, Inc.
 2,016,379 $63,032,007
7 CYTK
Cytokinetics Inc
 711,676 $60,627,678
8 BMRN
Biomarin Pharmaceutical Inc
 1,054,613 $60,344,955

All Filings in REPL

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $452,242 40,853
2026-03-31 $235,757 30,818
2025-12-31 $246,100 25,319
2025-09-30 $11,011,739 2,628,100
2025-06-30 $4,019,337 432,652
2025-03-31 $3,249,060 333,237